1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Opioid Induced Bowel Dysfunction-Pipeline Insights, 2016

Opioid Induced Bowel Dysfunction-Pipeline Insights, 2016

  • November 2016
  • -
  • Delve Insight
  • -
  • 60 pages


DelveInsight’s, “ Opioid Induced Bowel Dysfunction-Pipeline Insights, 2016”, report provides in depth insights on the pipeline drugs and their development activities around the Opioid Induced Bowel Dysfunction. The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Opioid Induced Bowel Dysfunction. DelveInsight’s Report also assesses the Opioid Induced Bowel Dysfunction therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please note:This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.

Scope
- The report provides competitivepipeline landscape of Opioid Induced Bowel Dysfunction
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Opioid Induced Bowel Dysfunction pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Opioid Induced Bowel Dysfunction and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Table Of Contents

Opioid Induced Bowel Dysfunction-Pipeline Insights, 2016

Illustrative Table of contents

- Opioid Induced Bowel Dysfunction Overview
- Opioid Induced Bowel Dysfunction Pipeline Therapeutics
- Opioid Induced Bowel Dysfunction Therapeutics under Development by Companies
- Opioid Induced Bowel Dysfunction Filed and Phase III Products
- Comparative Analysis
- Opioid Induced Bowel Dysfunction Phase II Products
- Comparative Analysis
- Opioid Induced Bowel Dysfunction Phase I and IND Filed Products
- Comparative Analysis
- Opioid Induced Bowel Dysfunction Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Opioid Induced Bowel Dysfunction - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Opioid Induced Bowel Dysfunction - Discontinued Products
- Opioid Induced Bowel Dysfunction - Dormant Products
- Companies Involved in Therapeutics Development for Opioid Induced Bowel Dysfunction
- Appendix
- Methodology
- Contact Us
- Disclaimer

List of Tables

- Number of Products under Development for Opioid Induced Bowel Dysfunction, 2016
- Number of Products under Development by Companies
- Comparative Analysis by Filed and Phase III Products, 2016
- Comparative Analysis Phase II Products, 2016
- Comparative Analysis Phase I and IND Filed Products, 2016
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2016
- Drug Candidates Profiles
- Opioid Induced Bowel Dysfunction Assessment by Monotherapy Products
- Opioid Induced Bowel Dysfunction Assessment by Combination Products
- Opioid Induced Bowel Dysfunction Assessment by Route of Administration
- Opioid Induced Bowel Dysfunction Assessment by Stage and Route of Administration
- Opioid Induced Bowel Dysfunction Assessment by Molecule Type
- Opioid Induced Bowel Dysfunction Assessment by Stage and Molecule Type
- Opioid Induced Bowel Dysfunction Therapeutics - Discontinued Products
- Opioid Induced Bowel Dysfunction Therapeutics - Dormant Products
- Products under Development by Companies, 2016

List of Figures

- Number of Products under Development for Opioid Induced Bowel Dysfunction, 2016
- Filed and Phase III Products, 2016
- Phase II Products, 2016
- Phase I and IND Filed Products, 2016
- Discovery and Pre-Clinical Stage Products, 2016
- Opioid Induced Bowel Dysfunction Assessment by Monotherapy Products
- Opioid Induced Bowel Dysfunction Assessment by Combination Products
- Opioid Induced Bowel Dysfunction Assessment by Route of Administration
- Opioid Induced Bowel Dysfunction Assessment by Stage and Route of Administration
- Opioid Induced Bowel Dysfunction Assessment by Molecule Type
- Opioid Induced Bowel Dysfunction Assessment by Stage and Molecule Type

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
North America Opioid Market Analysis By Product, By Application And Segment Forecasts To 2024

North America Opioid Market Analysis By Product, By Application And Segment Forecasts To 2024

  • $ 4950
  • Industry report
  • August 2016
  • by Grand View Research

The North America opioid market is expected to reach USD 18.5 billion by 2024, according to a new report by Grand View Research, Inc. Favorable regulations and healthcare reforms are providing an environment, ...

Global Market Study on Opioids: Widespread Usage in Treatment of Cancer to Drive the Growth of Opioids Market During the Forecast Period

Global Market Study on Opioids: Widespread Usage in Treatment of Cancer to Drive the Growth of Opioids Market During the Forecast Period

  • $ 4900
  • Industry report
  • August 2016
  • by Persistence Market Research

Opioids are naturally occurring opiates and synthetic and semi-synthetic drugs that act on opioid receptors in the brain and can cause dependence due to their euphoric effects. Opioids are majorly categorized ...

PAIN MANAGEMENT- NEW DISCOVERIES AND TREATMENT OPTIONS IN ABUSE DETERRENT ERA

PAIN MANAGEMENT- NEW DISCOVERIES AND TREATMENT OPTIONS IN ABUSE DETERRENT ERA

  • $ 3080
  • Industry report
  • September 2016
  • by MP Advisors

Rescheduling of Hydrocodone combinations from Class III to Class II, clear-cut regulatory guideline for Abuse Deterrent drug formulation NDA & ANDA (solid oral) filing and CDC guideline for Prescribing ...


Download Unlimited Documents from Trusted Public Sources

Opioid Market in the US

  • December 2016
    14 pages
  • Opioid  

  • United States  

View report >

Therapy Market in the UK

  • December 2016
    194 pages
  • Therapy  

    Infectious Dise...  

    Eye Disease  

  • United Kingdom  

View report >

Opioid and Anesthetics Market in Australia

  • December 2016
    5 pages
  • Opioid  

    Anesthetics  

    Analgesic  

  • Australia  

View report >

Related Market Segments :

Opioid

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.